<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307277</url>
  </required_header>
  <id_info>
    <org_study_id>19SARC05</org_study_id>
    <nct_id>NCT04307277</nct_id>
  </id_info>
  <brief_title>Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Grade 1 or 2 Soft Tissue Sarcoma</brief_title>
  <acronym>CHIC-STS01</acronym>
  <official_title>Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Grade 1 or 2 Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, multicenter, randomized open-label and comparative study designed to demonstrate
      whether adding 4 cycles of peri-operative doxorubicin-based chemotherapy improves
      metastasis-free survival as compared with standard management in patients with resectable
      FNCLCC grade 1/2 STS, considered as high-risk according to CINSARC (Complexity Index in
      SARComas) signature.

      After signed informed consent, patients considered as eligible to CHIC-STS study by the
      investigator will be enrolled in the study and a molecular screening will be performed (600
      patients will be screened).

      Patients considered as low-risk according to CINSARC signature will be treated at the
      discretion of the clinicians (prospective cohort).

      Patients considered as high-risk according to CINSARC signature will be randomized in the
      open-label multicenter phase III trial and assigned in one of the two following treatments
      arms:

        -  Arm A (control arm): Standard of care (surgical excision +/- external radiotherapy).

        -  Arm B (experimental arm): Standard of care + 4 cycles of intravenous chemotherapy during
           12 weeks.

      A total of 250 patients will have to be randomized with 125 patients in each arm.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis-free survival defined by the delay between randomization and the appearance of metastatic.</measure>
    <time_frame>5 years for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival defined by the delay between randomization and first relapse (local, regional, or distant) or death from any cause.</measure>
    <time_frame>5 years for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the toxicity grading of the National Cancer Institute (NCI-CTCAE v5.0).</measure>
    <time_frame>4 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival defined by the delay between randomization and death from any cause.</measure>
    <time_frame>5 years for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care + chemotherapy</intervention_name>
    <description>Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Surgical excision with external radiotherapy (if applicable)</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of soft-tissue sarcoma, histologically confirmed by RRePS (Réseau de
             Référence en Pathologie des Sarcomes et des Viscères) network

          2. According to FNCLCC grading system, grade 2 and grade 1 tumors

          3. Resectable and localized disease after appropriate extension work-up (including at
             least a chest-CT)

          4. Available archived FFPE tumor sample in sufficient quantity to allow CINSARC
             qualification

          5. Age ≥ 18 years

          6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          7. Life expectancy of at least 12 weeks after the start of the treatment

          8. Acceptable hematologic function (within 72 hours of eligibility assessment): Absolute
             neutrophil count (ANC) ≥ 1.5 G/L, Platelet count ≥ 100 G/L and Hemoglobin &gt; 9g/dL

          9. Acceptable renal function within 72 hours of eligibility assessment: Serum creatinine
             ≤ 1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min (by the Cockcroft and Gault
             formula)

         10. Acceptable liver function: Bilirubin ≤ 1.5 x upper limit of normal (ULN), AST (SGOT)
             and ALT (SGPT) ≤ 2.5 x ULN

         11. Normal LVEF (&gt;50%) measured by echocardiography or isotopic ventriculography

         12. Women should be post-menopaused or willing to accept the use of an effective
             contraceptive regimen during the treatment period and at least 12 months after the end
             of the treatment period. All non-menopaused women should have a negative pregnancy
             test within 72 hours prior to registration

         13. Signed written informed consent

         14. Patient affiliated to a Social Health Insurance in France.

        Exclusion Criteria:

          1. Soft-tissue sarcoma with the following histological subtypes: well-differentiated
             liposarcomas, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clear-cell
             sarcoma, epithelioid sarcoma, alveolar or embryonal rhabdomyosarcoma

          2. Primitive cutaneous, retroperitoneal, uterus or visceral STS

          3. Metastatic disease

          4. Previous or ongoing treatment for the sarcoma (with the exception of a surgery for
             diagnosis intend)

          5. Contra-indication for Doxorubicin, Ifosfamide and Dacarbazine treatments

          6. Prior therapy with ifosfamide or cyclophosphamide or other nitrogen mustards, and
             prior therapy with anthracyclines

          7. Prior mediastinal/cardiac radiotherapy

          8. History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable
             angina or poorly controlled arrhythmia, myocardial infarction within 6 months prior to
             study entry

          9. Prior or concurrent malignant disease diagnosed or treated in the last 2 years except
             for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell
             carcinoma, or in situ transitional bladder cell carcinoma

         10. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy

         11. Known infection with HIV, hepatitis B, or hepatitis C

         12. Women who are breastfeeding, pregnant or who plan to become pregnant while in the
             trial

         13. Concomitant disease or condition that could interfere with the conduct of the study,
             or that would, in the opinion of the investigator, pose an unacceptable risk to the
             subject in this study

         14. Patient who has forfeited his/her freedom by administrative or legal award or who is
             under legal protection (curatorship and guardianship, protection of justice)

         15. Patient unable to comply with the protocol for any reason.

        ADDITIONAL CRITERIA FOR THE RANDOMIZED PHASE III STUDY

          1. High-risk CINSARC signature

          2. External radiotherapy not initiated before randomization (if applicable).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thibaud VALENTIN</last_name>
    <phone>05 31 15 51 70</phone>
    <email>valentin.thibaud@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Loïc CHAIGNEAU</last_name>
      <phone>03 81 47 99 99</phone>
      <email>lchaigneau@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine ITALIANO</last_name>
      <phone>05 56 33 32 44</phone>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura MOÏSE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascale DUBRAY-LONGERAS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu LARAMAS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Valérie LE BRUN-LY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Armelle DUFRESNE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florence DUFFAUD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nelly FIRMIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thibaud VALENTIN</last_name>
      <phone>05 31 15 51 70</phone>
      <email>valentin.thibaud@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Soft Tissue Sarcoma</keyword>
  <keyword>CINSARC signature</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

